HanchorBio Prices IPO at NT$120 Ahead of Innovation Board Listing on May 29
The clinical-stage biotechnology company has completed bookbuilding for its oversubscribed initial public offering and secured OrbiMed as a strategic investor
HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, has announced the completion of bookbuilding for its initial public offering. Operating across Taipei, Shanghai, and San Francisco, the company has set its offering price at NT$120 per share ahead of its listing on the Taiwan Innovation Board.[1][2]
The initial public offering attracted strong interest from both domestic and international institutional investors, resulting in an oversubscribed book. Following the successful bookbuilding process, HanchorBio is expected to officially list on the Taiwan Innovation Board on May 29, 2026.[1][2]
As part of the offering, HanchorBio introduced OrbiMed, a leading global healthcare investment firm, as a strategic investor. The company stated that OrbiMed's participation represents an important example of overseas institutional investment in the biotechnology firm's market debut.[1]


